PMID- 23519173
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20151119
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 19
IP  - 3
DP  - 2013 Apr
TI  - Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.
PG  - 129-31
LID - 10.1097/RHU.0b013e318285f1e9 [doi]
AB  - Anti-tumor necrosis factor alpha (TNFalpha) medications have revolutionized the care of 
      children and adults with chronic arthritis. They are quick acting, highly 
      effective, and remarkably safe, particularly in children with juvenile idiopathic 
      arthritis (JIA). Anti-TNFalpha agents come in 2 basic varieties: monoclonal 
      antibodies to TNFalpha (e.g., infliximab, adalimumab) and a fusion protein containing 
      a TNF receptor (etanercept). Although hypersensitivity reactions are not uncommon 
      with some of the TNFalpha antibodies (e.g., infliximab), there are only rare reports 
      of anaphylaxis to subcutaneous injections of etanercept in adults with rheumatoid 
      arthritis. Herein, we report 2 cases of anaphylaxis in children with JIA after 
      etanercept injections. Although rare, pediatricians need to be aware of this 
      potentially dangerous occurrence.
FAU - Crayne, Courtney B
AU  - Crayne CB
AD  - School of Medicine, University of Alabama, Birmingham, AL, USA.
FAU - Gerhold, Kerstin
AU  - Gerhold K
FAU - Cron, Randy Q
AU  - Cron RQ
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
MH  - Adalimumab
MH  - Adolescent
MH  - Anaphylaxis/*chemically induced/*diagnosis/drug therapy
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antirheumatic Agents/*adverse effects/*therapeutic use
MH  - Arthritis, Juvenile/*drug therapy
MH  - Child
MH  - Epinephrine/therapeutic use
MH  - Etanercept
MH  - Female
MH  - Histamine Antagonists/therapeutic use
MH  - Humans
MH  - Immunoglobulin G/*adverse effects/*therapeutic use
MH  - Injections, Subcutaneous
MH  - Male
MH  - Prednisolone/therapeutic use
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2013/03/23 06:00
MHDA- 2013/09/27 06:00
CRDT- 2013/03/23 06:00
PHST- 2013/03/23 06:00 [entrez]
PHST- 2013/03/23 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - 10.1097/RHU.0b013e318285f1e9 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2013 Apr;19(3):129-31. doi: 10.1097/RHU.0b013e318285f1e9.